News | Heart Valve Technology | November 10, 2016

Henry Ford Hospital Cardiologist Performs Pioneering Laser Mitral Valve Treatment

LAMPOON procedure provides option for patients needing mitral valve replacement who are not eligible for open-heart surgery or transcatheter replacement

Greenbaum, Henry Ford Hospital, LAMPOON procedure, mitral valve

November 10, 2016 — A Henry Ford Hospital cardiologist is pioneering a promising new procedure to improve the success of mitral valve replacement.

Interventional cardiologist Adam Greenbaum, M.D., medical co-director of the Center For Structural Heart Disease at Henry Ford Hospital, believes the procedure — slicing a leaflet with an electrified wire through a tiny catheter before replacing a mitral valve — will save thousands of lives.

Greenbaum helped perform the first procedure in man on May 25, 2016 at Emory University in Atlanta and led the second procedure at Henry Ford Hospital on June 8. Since then, cardiologists have performed nine of the highly specialized procedures, six at Henry Ford Hospital.

“It’s in its infancy, but was successful in all patients,” said Greenbaum. “It’s extremely invigorating to say someone who had no options now has a beautifully working mitral valve, repaired in a safe manner with the use of only catheters. This could be life-saving for many people.”

The procedure is medically described as ‘laceration of the anterior mitral valve leaflet to prevent outflow track obstruction,’ and nicknamed with the acronym “LAMPOON.”

The LAMPOON procedure is designed for patients who need a new mitral valve. The mitral valve regulates the flow of blood between the left top and bottom chambers of the heart after it has been oxygenated in the lungs. The ventricle then squeezes the blood out through the aortic valve and into the body.

Doctors can replace a mitral valve two ways: through open-heart surgery, or by deploying a valve through a small catheter guided through blood vessels and into the heart if patients are felt to be too sick for open surgical repairs. But in up to 50 percent of patients, the heart’s anatomy can cause problems. In some people, when the cardiologist positions and opens the new mitral valve, the  original valve leaflet gets pushed back and can block blood flow out of the heart. The complication is fatal.

In open-heart surgery, doctors cut away the blocking tissues. That is not an option for those too sick to undergo open-heart surgery, leading Greenbaum and his team to search for an alternative.

In the catheter-based LAMPOON procedure,  the cardiologist weaves a catheter through the patient’s blood vessels and into the heart. The doctor then uses an electrified wire about the size of a sewing thread woven through the catheter to slice away the problem tissue.

“We don’t know how many people have been turned away due to their anatomic risk,” said Greenbaum. “Now we think we have conquered that obstacle.”

Greenbaum has been working with interventional cardiologist Robert J. Lederman, M.D., and fellow Jaffar Khan, M.D., at the National Heart, Lung, and Blood Institute, who first performed the technique in animals; and Vasilis C. Babaliaros at Emory University School of Medicine, who performed the first human procedure in May.

Greenbaum and Lederman also performed the first transcaval access procedure in man, a novel way to access the heart by connecting blood vessels in the abdomen. A multi-center study of the procedure recently reported a 98 percent success rate for the procedure.

For more information: www.henryfordhospital.com

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init